e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis
Kreuter Michael, Wijsenbeek Marlies S., Vasakova Martina, Spagnolo Paolo, Kolb Martin, Costabel Ulrich, Weycker Derek, Kirchgaessler Klaus-Uwe, Maher Toby M.
Source:
Eur Respir J 2016; 47:1776-1784
Journal Issue:
June
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Kreuter Michael, Wijsenbeek Marlies S., Vasakova Martina, Spagnolo Paolo, Kolb Martin, Costabel Ulrich, Weycker Derek, Kirchgaessler Klaus-Uwe, Maher Toby M.. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47:1776-1784
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Source: Eur Respir J 2016; 48: 1523-1524
Year: 2016
Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns
Source: Eur Respir J 2016; 48: 1524-1526
Year: 2016
LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases
Year: 2015
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
ERJ June Podcast: unfavourable effects of oral anticoagulants on survival in idiopathic pulmonary fibrosis
Source: Eur Respir J 2016; 47:E66
Year: 2016
Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012
Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 628s
Year: 2006
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017
Year: 2017
Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
Source: Eur Respir J 2001; 17: 337-342
Year: 2001
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018
Year: 2019
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study
Source: Eur Respir J 2012; 40: 101-109
Year: 2012
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Long-term efficacy and safety of N-acetylcysteine inhalation in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept